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Abstract
Background: Breast cancer comprises clinically and molecularly distinct tumor subgroups that differ in cell
histology and biology and show divergent clinical phenotypes that impede phase III trials, such as those utilizing
cathepsin K inhibitors. Here we correlate the epithelial-mesenchymal-like transition breast cancer cells and
cathepsin K secretion with activation and aggregation of platelets. Cathepsin K is up-regulated in cancer cells that
proteolyze extracellular matrix and contributes to invasiveness. Although proteolytically activated receptors (PARs)
are activated by proteases, the direct interaction of cysteine cathepsins with PARs is poorly understood. In human
platelets, PAR-1 and −4 are highly expressed, but PAR-3 shows low expression and unclear functions.
Methods: Platelet aggregation was monitored by measuring changes in turbidity. Platelets were immunoblotted
with anti-phospho and total p38, Src-Tyr-416, FAK-Tyr-397, and TGFβ monoclonal antibody. Activation was
measured in a flow cytometer and calcium mobilization in a confocal microscope. Mammary epithelial cells were
prepared from the primary breast cancer samples of 15 women with Luminal-B subtype to produce primary cells.
Results: We demonstrate that platelets are aggregated by cathepsin K in a dose-dependent manner, but not by
other cysteine cathepsins. PARs-3 and −4 were confirmed as the cathepsin K target by immunodetection and
specific antagonists using a fibroblast cell line derived from PARs deficient mice. Moreover, through co-culture
experiments, we show that platelets activated by cathepsin K mediated the up-regulation of SHH, PTHrP, OPN, and
TGFβ in epithelial-mesenchymal-like cells from patients with Luminal B breast cancer.
Conclusions: Cathepsin K induces platelet dysfunction and affects signaling in breast cancer cells.
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Background
Proteases from epithelial, myoepithelial, stromal, and tumor
cells become activated during neoplastic progression and
can display causal roles in tumor growth, migration, inva-
sion, angiogenesis, and metastasis [1–5]. However, identifi-
cation of the exact tissue of origin, temporal release, and
activation is not fully established.
Human cysteine cathepsins (Cat) are proteases that are
highly up-regulated in a wide variety of cancers. Active
forms of cathepsins are localized in endosomal or lysosomal
vesicles, cell membranes, and/or secreted and localized in
pericellular environments as soluble enzymes that are in-
volved in cleaving the extracellular matrix proteins, laminin
and type IV collagen, and cell-adhesion proteins such as E-
cadherin and matricellular proteins [2, 6–8].
Proteolytically activated receptors (PARs) constitute a
family of G-protein-coupled receptors that are activated
during one of several protease-generating pathways in
humans, such as inflammatory, fibrinolytic, and hemostatic
pathways and cancer; PARs are also activated by proteases,
particularly thrombin, via a specific proteolytic cleavage of
their amino-terminal exodomain [9–12]. The PAR-
mediated mitogenic pathway regulates tumor cell growth
and can promote tumor cell invasion [13]. Several examples
of PARs up-regulation and their potential in activating pro-
teinases in tumor tissues, including breast, prostate, and
colon cancer, and malignant melanomas, have been re-
ported [11, 14]. In addition, abnormalities in blood coagula-
tion are common in malignant tumors [15]. Tumor cells
have platelet aggregating activity that occurs through differ-
ent mechanisms including the activation of PARs. PAR-1
and −4 show the highest expression in human platelets
among the four currently identified PARs [16, 17]. PAR-3
shows the lowest expression and appears to be preferen-
tially expressed in cells of hematopoietic origin, suggesting
a function distinct from that of PAR-1, which is the major
receptor involved in thrombin-mediated platelet activation
[18]. Furthermore, PAR-3 has been shown to be a major
thrombin receptor in mouse platelets; however, its role in
humans remains uncharacterized [11, 19–21]. In this sce-
nario, the link between human cysteine cathepsins and
platelet functions in malignant conditions is underexplored.
The cysteine cathepsins used in our study, K, L, V, S,
and B, are particularly attractive drug targets [8, 22]. Cat
K is of relevant interest because it is a cysteine protease
implicated in bone remodeling, breast cancer progres-
sion, and other diseases [23–26].
We investigated platelet aggregation using washed
platelets, which enabled the identification of PARs in-
volved in this process, to determine the role of cathep-
sins in human platelet aggregation and the detailed
triggering signal produced by cathepsins on platelets. In
addition, we examined whether Cat K alone, which was
activated in epithelial-mesenchymal cells from women
with breast cancer or its co-culture with Cat K activated
human platelets, could directly affect the expression of
ligands in the Hedgehog signaling pathway. The expres-
sion of these ligands, reported as an aberrantly activated
and proto-oncogenic pathway in breast cancer, is related
to bone metastasis markers.
Methods
A detailed material and methods section can be found in
the Additional file 1.
Collection of human platelets
Human platelets were obtained from donors within the
Charitable Association of Blood Collection – COLSAN
in São Paulo, SP, Brazil. The study was carried out in ac-
cordance with the Declaration of Helsinki and approved
by the Institutional Ethics Review Board (Ethics Com-
mittee in research of the Federal University of São Paulo
- CEP1917/11) from the São Paulo Federal University/
São Paulo Hospital (UNIFESP-HSP). A written informed
consent was signed by each patient, who volunteered to
participate before the study start.
Enzyme preparation
The K, L, S, V, and B cysteine proteinase cathepsins
were purified as previously described [27]. Papain was
obtained from Sigma (St Louis, MO, USA) and Human
α-thrombin (200 NIH units/mg) was purchased from
Helena Laboratories (Beaumont, Texas, USA).
Platelet aggregation
Pooled venous blood was collected from healthy donors to
obtain platelet-rich plasma (PRP); washed platelets were
prepared as previoulsy described [28]. Agonist solutions
containing each of the cysteine proteinases cathepsins were
added (separately one by one) to the washed platelets ali-
quot: Cat K (20 nM), cathepsins L, V, S, and B (all enzymes
at 0.2 μM), and papain (1.6 μM). α-Thrombin (1.0 UNIH/
500 μl), 0.2 μM activating peptides-PAR1 (AP-PAR-1), or
200 μM AP-PAR-4 were used as agonists for aggregation in
washed platelet suspensions. Enzymes, preincubated with
cysteine inhibitors (E-64 (5 μM), LWMK (1.0 μM), and
HWMK (1.0 μM)), and platelets pretreated with PAR-3
antibody and PAR-1 (SCH 79797), and PAR-4 (trans-cinna-
moyl-YPGKF-NH2) antagonists were tested as blockers for
Cat K-induced platelet aggregation.
Peptide synthesis
FRET peptide substrates containing sequences from
PAR-1, −3, and −4 proteinase-activated receptors were
synthesized as previously described [29]. The molecular
mass and purity of synthesized peptides were assessed
by analytical HPLC and MALDI-TOF using a Microflex
-LT mass spectrometer (Bruker – Daltonics, Billerica,
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MA, USA). Stock solutions of peptides were prepared in
dimethyl formamide, and their concentrations were de-
termined spectrophotometrically using the 2,4-dinitro-
phenyl group (Dnp) molar extinction coefficient of
17.300 M−1cm−1 at 365 nm.
Hydrolysis of PARs derived FRET substrates by human
cathepsins cysteine proteinases
The hydrolysis of FRET peptides by human cysteine ca-
thepsins was performed as previously described [30].
The Vmax and KM kinetic parameters were determined
from the initial rate measurements at 8–10 substrate
concentrations between 0.15 and 5 KM. Enzyme concen-
trations were chosen so that less than 5 % of the sub-
strate was hydrolyzed during the assay. The reaction rate
was converted to micromoles of hydrolyzed substrate
per minute based on a calibration curve obtained by the
complete hydrolysis of each peptide. The data were fitted
with the respective standard errors to the Michaelis-
Menten equation using the GraFit software (Erithacus
Software Limited). At least duplicate data were collected
in all assays; the error values were less than 10 % for
each of the obtained kinetic parameters.
Extraction and real-time reverse transcription-PCR
analysis
Total RNA was isolated from Cat K treated and un-
treated human platelets to detect PAR-3 expression.
cDNA was generated using the ImProm-IITM reverse
transcription kit (Promega, Madison, WI, USA). The
quantitative RT-PCR performance data is presented in
the Additional file 1.
Protein preparation and immunoblot analysis
Washed platelets were treated with cathepsins cysteine pro-
teinases K (20 nM), L, V, S, and B (all enzymes at 0.2 μM),
papain (1.6 μM), and α-thrombin (0.001 UNHI/mL) for
10 min at 37 °C for the detection of PARs −1, −3, and −4
and extraction of signaling phospho proteins into platelets
(p-PKC, p-SOD, p-Src family, p-FAK, and p-p38). Whole
cell lysates were collected in 20 mM Tris buffer containing
300 mM NaCl, 2 mM EGTA, and 2 % Nonidet P-40. Co-
culture was performed for the detection of Src, p-Src, FAK,
p-FAK, PTHrP, Cat K, OPN, SHH, and TGFβ. Total pro-
tein (60 μg) was assessed by SDS-PAGE gel and transfer to
nitrocellulose membranes. See Additional file 1 for details.
Platelet activation
The activation of washed human platelets was assessed
using fluorescence-activated cell sorting (FACS) by Accuri
C6 (BD-Biosciences, San Jose, CA, USA). Human platelets
were detected using CD61-FITC labeling (GPIIIa – integrin
β3) as a specific marker. The light scatter and fluorescence
channels were set at a logarithmic gain. PRP cells (5 × 107
cells/mL) were treated with α-thrombin (0.001 U/mL),
cathepsins K (20 nM), L, V, S, and B (all enzymes at
0.2 μM), and papain (1.6 μM) for 10 min at 37 °C. The ex-
posure of phosphatidylserine was monitored using
annexin-V-PE labeling according to the manufacturer’s in-
structions (BD Pharmingen, San Diego, CA, USA) and
identified by cytofluorometry. Platelet lysis, determined by
lactate dehydrogenase release, was not observed. We used
apyrase (5.0 UNIH/mL), an ATP-diphosphohydrolase, to
prevent ADP amplification in platelet activation.
Calcium mobilization by confocal microscopy
Washed human platelets were incubated with 4 μM Fluo-
4/AM (Molecular probes, Invitrogen, USA) at room
temperature for 30 min. After incubation, washed platelets
were centrifuged at 141 × g for 5 min for subsidence to cov-
erslips (12 mm diameter). Briefly, platelets were stimulated
with cathepsins K (20 nM), L, V, S, and B (all enzymes at
0.2 μM), papain (1.6 μM), and α-thrombin (1.0 U/mL);
Fluo-4/AM was excited with an argon laser (λEx = 488 nm)
and light emission was detected using a Zeiss META de-
tector (λEm = 500–550 nm). See Additional file 1 for details.
Tissue isolation and cell culture
Thrombin receptor (ThrR−/−) knockout mice were ob-
tained from CEDEME at the Federal University of São
Paulo (UNIFESP, São Paulo, Brazil). All mice were
housed and handled in accordance to the guidelines pro-
posed by the Brazilian Council for Animal Experimenta-
tion (COBEA) and approved by the Research Ethics
Committee of the Federal University of São Paulo, São
Paulo, Brazil, under number 0858/10. The isolation and
preparation of fibroblast cell lines were adapted from
Trejo et al. [31].
Mammary tissues were obtained from informed volun-
teers in the mastology Unit/Department of Gyne- cology
at the Federal University of São Paulo/São Paulo Hos-
pital (UNIFESP/HSP) with approved Ethics Committee
in research of the Federal University of São Paulo
(CEP1917/11). A written informed consent was signed
by each patient, who volunteered to participate before
the study start. Primary mammary cell culture was pre-
pared from biopsies from 15 women who had luminal B
subtype breast cancer (each tumor was analyzed for ER/
PR/HER2 and Ki-67 high (≥14 % cells positive) status)
and an average platelet count of 635 (× 103/μL). Tissue
samples were rinsed, minced into small pieces, and digested
with collagenase IA (0.05 mg/ml) for 16 h at 37 °C. After
this incubation, samples were centrifuged (differential cen-
trifugation) to separate stromal and epithelial cells. Cells
were placed in primary flasks (Becton–Dickinson Labware,
Le Pont de Claix, France) and cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM)/F-12 without phenol red and
with 10 % fetal bovine serum (FBS) supplemented with
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10 μg/mL insulin, 20 ng/mL epidermal growth factor,
0.5 μg/mL hydrocortisone, 100 ng/mL cholera toxin, and
1 % penicillin/streptomycin in a humidified incubator at
37 °C and 5 % CO2. After 24 h incubation, non-adherent
cells were washed out, and adherent epithelial cells were
characterized by immune staining with FITC-labeled anti-
cytokeratin, E-cadherin, N-cadherin, PAI-1, claudin, and
Cy3-labeled anti-vimentin antibodies.
Zymography
Conditioned media from primary cells (epithelial and
epithelial-mesenchymal-like transition phenotype) were
collected and centrifuged to remove cellular debris. Vol-
umes of conditioned media normalized to the number of
cells were subsequently mixed with the sample buffer
and loaded onto a 7.5 % acrylamide/bisacrylamide separ-
ating gel containing 0.02 % (w/v) gelatin. After electro-
phoresis, the gel was incubated in 2.5 % Triton X-100,
rinsed in distilled water, and incubated for 16 h at 37 °C
in buffer containing 50 mM Tris pH 7.6, 20 mM NaCl,
5 mM CaCl2, and 2 μM ZnCl2. The gel was stained with
0.1 % Coomassie blue R-250, 30 % methanol, and 10 %
acetic acid, and destained in the same solution without
Coomassie blue.
Treatment of tumor cells with Cat K activated platelets
Cells were seeded in DMEM-F12 (as see above) and in-
cubated overnight. After this incubation, a total of
200,000 platelets/μl in fresh medium was immediately
treated with Cat K (20 nM). Platelets were removed for
analysis, and epithelial-mesenchymal-like cells and epi-
thelial cells were washed twice with PBS. Western blot
was performed to identify the proteins involved in the
amplification of the Hedgehog pathway (Src, SHH,
PTHrP, Cat K, OPN, and TGFβ).
Phenotypic analysis of breast cancer cells and Cat K
activated platelets
Epithelial-mesenchymal-like transition cells co-cultured
with washed human platelets activated by Cat K were sub-
mitted to phenotypic analysis. Platelets were removed for
analysis, and epithelial-mesenchymal-like cells were washed
twice with PBS and adjusted to 1 × 106/mL. Cell suspen-
sions were incubated for 30 min at room temperature and
in the dark with CD44-phycoerythrin (PE) and washed
platelets were incubated with P-selectin-fluorescein isothio-
cyanate (FITC) for labeling according to the manufacturer’s
instructions (BD Pharmingen, San Diego, CA, USA). Cells
were fixed with 4 % paraformaldehyde and analyzed using a
Becton Dickinson and Company flow cytometer (Accuri
C6™).
Statistical analysis
The results from the in vitro studies are presented as means
of three independent experiments. The statistical analysis
was performed using GraphPad PRISM5.0 (La Jolla, CA).
Briefly, the Student’s t-test was used to compare means be-
tween two independent groups, whereas one-way ANOVA
followed by the Tukey’s post-test, was used to compare
means between two or more independent groups. Two-way
ANOVA was used to compare group means influenced by
two independent factors. The error bars represent the SEM
in some of the figures, and SD in others. The level of p ≤
0.05 was accepted as significant.
Results
Cat K induced aggregation in human platelets
The human cysteine cathepsins’ ability to induce platelet
aggregation was evaluated through the individual addition
of K, L, V, S, and B cathepsins, at final concentrations of up
to 20 nM, to washed human platelets suspensions; aggrega-
tion curves were recorded for 6 min in an aggregometer.
Papain (1.6 μM) and α-thrombin (1.0 UNHI/mL) were used
as agonist controls. The L, V, S, and B cathepsins at a me-
dian effective dose (ED50) of 0.2 μM failed to induce any
measurable aggregation while Cat K showed an effect of up
to 40 % aggregation, similar to that observed with papain
(Fig. 1a-c).
Similar aggregation patterns were observed in all
assayed concentrations; however, the aggregation magni-
tude showed a linear correlation with Cat K concentra-
tions in the 2.5–20 nM range; further increase in
concentrations, up to 40 nM, did not show improved ag-
gregation levels (Fig. 1d, e). The maximal extent of ag-
gregation obtained at 20 nM was 46.8 ± 10 %.
Moreover, the type of aggregation clot induced by Cat
K differed from the characteristic clot induced by α-
thrombin. The Cat K lag phase was followed by a second
aggregation wave that induced the formation of micro-
aggregates, whereas α-thrombin showed a biphasic curve
with the formation of a tight and irreversible characteris-
tic platelet clot (Fig. 1f ).
The proteolytic nature of this activation was confirmed
by the complete inhibition of platelet aggregation when
Cat K (20 nM) and papain (1.6 μM) were preincubated
with the irreversible cysteine proteinase inhibitor E-64
(5 μM), or the human high and low molecular weight ki-
ninogen (HMWK and LMWK at 1.0 μM; Fig. 1g). The
level of platelet aggregation observed when α-thrombin
was further added to the system confirmed that these
three cysteine protease inhibitors did not interfere with
the platelets’ ability to respond to α-thrombin activation
(Fig. 1g).
Table 1 shows the in vitro kinetic parameters of the
hydrolysis of synthetic FRET substrates, and their cleav-
age sites derived from sequences that span the cleavage
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sites for PARs −1, −3, and −4 activations by Cat K, pa-
pain, and α-thrombin. The peptide derived from the
PAR-2 sequence was not included in this study because
PAR-2 is not present in platelets (Additional file 1: Table
S1). Z-F-R-MCA, the standard substrate for papain and
Cat K, was assayed as the positive control for both en-
zymes [7, 27, 32–34]. All three PAR substrates were
cleaved by both cysteine proteinases with kcat/KM values
in the same order of magnitude as Z-F-R-MCA. The
PAR-1 substrate was only hydrolyzed between Leu and
Qln-EDDnp, a peptide bond not available in the PAR-1
sequence. Cat K and papain effectively cleaved PAR-3
and PAR-4 peptides at the Lys-Thr and Arg-Gly bonds,
mimicking the α-thrombin activity on this substrate and
supporting both enzymes as PAR-3 and PAR-4 agonists.
The PAR-3 peptide was hydrolyzed by Cat K only at the
Lys-Thr peptide bond forming the tethered ligand se-
quence of PAR-3 TFRGAP; nevertheless, the presence of
other papain cleavage sites on PAR-3 indicates a possible
antagonistic effect. The kinetic hydrolysis parameters
and PARs-1, −3, and −4 peptides cleavage sites used by
cat L, S, V, and B are shown in Table 2.
Distinguished effect of Cat K on thrombin-induced human
platelet aggregation
The Cat K pre-stimulation in these washed platelets
cells increased α-thrombin promoted platelet aggrega-
tion (Fig. 2a, black and green lines). However, Cat K
a
b
c
d
e
g
f
Fig. 1 Cat K-induced human platelet aggregation. Dose-response curve and effect of LWMK, HWMK, and E-64 under cat K activity. The washed
human platelets (3.0 x 105/mL) function was measured at baseline and stimulus was added after 30 s. (a) Effect of cat K (20 nM) and papain (1.6
µM) on platelet aggregation. (b) Negative effect of cathepsins L, V, S, and B (at a median effective dose - ED50 - of 0.2 µM) on platelets showing
typical tracing results, α-thrombin (1.0 UNIH/500 µL) was used as the agonist control. (c) The bar graph shows percentage of aggregation. Data
are presented as means ± SEM (***p<0.0001). Traces show one typical experiment out of at least six. (d) Solutions containing different
concentrations of cat K (2.5 to 30 nM) were added to platelets and aggregation was measured as described. Representative traces showing the
typical aggregation induced by cat K at different concentrations and α-thrombin (1.0 UNIH/500 µL). (e) Concentration-response bar graph
expressed as percentage of aggregation (***p<0.001). (f) Clot aggregate analyses of human platelets treated with cat K (20 nM) and α-thrombin
(1.0 UNIH/500 µL). (g) Inhibition of human cat Kactivity (black line) and papain (blue line) on human platelet aggregation by E-64 (5 µM), LWMK
(1.0 µM) + HWMK (1.0 µM)
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did not affect platelet aggregation when added after
α-thrombin (Fig. 2a, blue and red lines).
Conversely, no aggregation was observed when
platelets were stimulated by α-thrombin after the
addition of cat L (0.2 μM) (Fig. 2b, orange line). The
same antagonistic effect was observed with the hu-
man cysteine cathepsins V, S, and B (data not shown).
The addition of papain (1.6 μM) after α-thrombin
led to a decay in the α-thrombin effect on platelet ag-
gregation (Fig. 2b, blue line). Overall, the maximal ag-
gregation extent in α-thrombin stimulated platelets
decreased from 90 % ± 10 to 60 % ± 5, with a p <
0.001 (Fig. 2b, black and red lines). The observed
decay in α-thrombin-induced platelet aggregation
indicates that PAR-4 was papain activated and PAR-1
activity was eliminated, which is the major receptor
used by α-thrombin in the process of platelet
aggregation.
Because papain and Cat K cleaved PAR-3 and PAR-4
peptides at their activation sites (Lys-Thr and Arg-Gly
bonds, respectively; Table 1), the interference of Cat K
on the activity of papain in platelet aggregation was
assayed. A small decrease in Cat K-induced platelet
aggregation was observed when Cat K was added to hu-
man platelets before papain (Fig. 2c, d, black and red
lines). When Cat K was added 2 min after the addition
of papain, a significant decrease of 20 % ± 4 in platelet
aggregation was observed (Fig. 2c-e).
Table 2 Kinetic parameters for the hydrolysis of the FRET peptides derived from sequences that span the cleavage sites for
activation of protease-activated receptor (PAR) 1,3 and 4 by human cathepsins, L, S, V and B
Enzyme Peptide Abz-eptidyl-EDDap % kcat (s
-1) Km (µM) Kcat/Km (s
-1 µM-1)
Cathepsin L Z-FR-MCA[27] - - 17.6 1.3 13.5
- PAR 1 TL↓DPRSFL↓L↓Q↓ L↓D-30/L↓L-32/L↓Q-16/Q↓Eddnp-22 3.5 2.2 1.6
+ PAR 3 TLPIK↓TFR↓GQ K↓T-45/R↓G-55 10.6 3.9 2.7
nh PAR 4 LPAPRGYPGQ - - - -
Cathepsin S Z-FR-MCA[32] - - 2 21 0.09`
+ PAR 1 TLDPR↓SFLL↓Q R↓S-24/L↓Q-76 1.2 4.2 0.29
+ PAR 3 TLPIK↓TFR↓GQ K↓T-36/R↓G-64 0.3 8.1 0.04
- PAR 4 LPAPRG↓YPGQ -
Cathepsin V Z-FR-MCA [27] - - 0.71 6.4 0.11
- PAR 1 TLDPR↓SFL↓L↓Q R↓S-55/L↓L-2/L↓Q-R3 0.01 1.0 0.01
+ PAR 3 TLPIK↓TF↓R↓GQ K↓T-74/F↓R-15/R↓G-11 0.78 1.9 0.41
+ PAR 4 LPAPR↓GYPG↓Q R↓G-75/G↓Q-43 - - -
Cathepsin B Abz-FRA (eDnp)K[34] - - 16.9 13.4 1.33
nh PAR 1 TLDPRSFLLQ - - - -
nh PAR 3 TLPIKTFRGQ - - - -
nh PAR 4 LPAPRGYPGQ - - - -
Assay conditions: [32] Bromme et al., 1994; [27] = Bromme et al., 1999; [34] Almeida et al., 2001. Enrichment of PAR-2 of kinetic parameters see Supplementary
content, Table S1
Table 1 Kinetic parameters for the hydrolysis of the FRET peptides derived from sequences that span the cleavage sites for
activation of protease-activated receptors (PAR) 1, 3 and 4 by cat K and papain
Enzyme Peptide Abz-peptidyl-EDDnp % Kcat (s
-1) Km (µM) kcat/Km (s
-1 µM-1)
Cathepsin K Z-FR-MCA[7] - - 12.8 9.7 1.31
- PAR 1 TLDPRSFLL↓Q - 2.4 8.5 0.28
+ PAR 3 TLPIK↓TFRGQ K↓T-96% 2.0 4.3 0.47
+ PAR 4 LPAP↓R↓GYPG↓Q P↓R-44/R↓G-20/G↓Q-36 1.0 3.3 0.30
Papain Z-FR-MCA[33] - 42 89 0.47
- PAR 1 TLD↓PRSFL↓L↓Q D↓P-1/L↓L-3/L↓Q-96 0.04 0.5 0.08
+ PAR 3 TLPIK↓TF↓R↓GQ K↓T-46/F↓R-24/R↓G-30 0.22 1.3 0.17
+ PAR 4 LP↓AP↓R↓GYPGQ P↓A-40/P↓R-48/R↓G-12 0.31 0.9 0.34
Assay conditions: [7] Lecaille et al., 2008; [33] Del Nery et al., 2000. Enrichment of PAR-2 kinetic parameters see Supplementary content, Table S1.
Andrade et al. BMC Cancer  (2016) 16:173 Page 6 of 19
The Cat K effect on platelets is blocked by the PAR-3 anti-
body and PAR-4 antagonist
The blockage of the Cat K effect was evaluated using
PAR-1 and PAR-4 specific antagonists (SCH 79797 and
trans-cinnamoyl-YPGKF-NH2, respectively) and PAR-3
antibody, also described as a PAR-3 antagonist [35].
The presence of 140 nM PAR-1 antagonist SCH
79797 decreased the Cat K-induced platelet
aggregation by 20 % and, as expected, completely
blocked the action of PAR-1-AP (0.2 μM) agonist con-
trol (Fig. 3a). The pre-incubation of washed human
platelets with the specific PAR-4-antagonist (30 μM)
completely abolished the aggregation induced by Cat
K (Fig. 3b) and papain (data not shown). In addition,
the pre-incubation of human platelets with the PAR-3
antibody (0.02 μM) promoted a complete inhibition of
a b
c
e
d
Fig. 2 The influence of cat K (20 nM), papain (1.6 µM), and cat L (0.2 µM) on the effect of α-thrombin. (a) The results show platelet aggregation
induced by cat K (20 nM) followed by α-thrombin stimulation (1.0 UNIH/500 µL) after 2 min. α-Thrombin stimulation was slightly prolonged
(black line). Cat K does not interfer with α-thrombin activity on platelets aggregation (blue line). Data are expressed as mean ± SEM from 6
independent experiments (*p<0.05). (b) Papain (1.6 µM) followed by α-thrombin stimulation (1.0 UNIH/500 µL) (blue line). The inverse stimulation
(α-thrombin followed by papain (1.6 µM) and cat L (0.2 µM)), (black and orange lines). The bar graph shows percentage of aggregation expressed
as mean ± SEM from 3 independent experiments (**p<0.01, ***p<0.001). (c) Representative traces showing typical aggregation induced by cat K
(20 nM), papain (1.6 µM), and α- thrombin (1.0 UNIH/500 µL). The arrows indicate when agonists were added. (d) Stimulation by papain (1.6 µM)
followed by cat K (20 nM), red line. Inverse cat K stimulation (20 nM) followed by papain (1.6 µM), black line. (e) The bar graph shows
percentages of aggregation. Data are expressed as mean ± SEM from 3 independent experiments (*p<0.05)
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Fig. 3 (See legend on next page.)
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the Cat K-induced platelet aggregation. Moreover, the
addition of α-thrombin at the end of the experiment
showed that it still promoted platelet aggregation
(Fig. 3c). Conversely, the PAR-3 antibody only inhib-
ited approximately 40 % of the papain-induced platelet
aggregation. The presence of PAR-3 on the surface of
human platelets was confirmed by the detection of
PAR-3 transcripts and protein through RT-PCR and
Western blot analyses (Fig. 3d, e).
Fibroblast cells from ThrR−/− mice were loaded with
fura-2, and ratiometric calcium imaging was obtained
after incubation with Cat K, papain, and α-thrombin.
The responses and single-cell imaging are shown in
Fig. 3f-h. Both Cat K and papain were found to activate
PAR-4, however, only Cat K activates PAR-3. The activa-
tion of PAR-3 and PAR-4 by Cat K was completely
blocked by E-64. Cat K did not activate PAR-1.
Cat K triggers the activation of Src and promotes p38
Mitogen-activated protein kinase (MAPK) phosphorylation
in human platelets
The possible involvement of the Src pathway was stud-
ied to gain better insights into the signaling involved in
the Cat K-induced platelet aggregation. The treatment of
washed platelets with Cat K (20 nM) led to Src-Tyr-416
and FAK-Tyr-397 activation. Cat K induced Src-Tyr-416
and slightly induced FAK-Tyr-397 phosphorylation with
pSrc/total Src and pFAK/total FAK ratios of 4.04 ± 0.2
and 2.1 ± 0.4, respectively (Fig. 4a, b). As expected, the
treatment with α-thrombin resulted in increased Src phos-
phorylation with a pSrc/total Src ratio of 6.2 ± 0.3, and in-
creased FAK phosphorylation with a pFAK/total FAK
ratio of 6.3 ± 0.2 (p ≤ 0.01 and p ≤ 0.001, Fig. 4a, b respect-
ively). Papain (1.6 μM) slightly induced Src- and FAK-
phosphorylation (2.1 ± 0.2 and 2.5 ± 0.4, respectively). The
use of PAR-4 antagonist and PAR-3 antibody eliminated
the phosphorylation of Src Tyr416 by Cat K (data not
shown).
We investigated the involvement of p38 MAPK in the
process of Cat K activation to gain insight into the bio-
chemical pathway involved in Cat K-induced platelet ag-
gregation. The phosphorylation of p38 was required
when human platelets were stimulated with Cat K. Our
results demonstrated p38-MAPK phosphorylation by
Cat K-stimulated platelet activation (4.2 ± 0.2, Fig. 4c), as
observed with α-thrombin (6.32 ± 0.4) and papain (4.62
± 0.4, Fig. 4c). Under these conditions, a significant p38-
MAPK phosphorylation by Cat L, S, and V, which share
about 24 to 60 % amino acids sequence identity with Cat
K (data not shown), was not observed. This result sug-
gested that the excessive p38 phosphorylation could be a
marker for platelet stress through a detectable release of
lactate dehydrogenase and enhanced caspase-3 activity
(Additional file 1: Figure S1a-c).
Cathepsin K showed sustained Ca2+ mobilization
PARs trigger the transmission of primary activation sig-
nals through the phosphorylation of downstream tyro-
sine or serine/threonine residues in protein kinases. The
sequence of kinases phosphorylation is recruited to
transmit activating signals of Ca2+ release from the con-
tents of platelets, which result in shape alteration, inter-
actions with others platelets and finally clot stabilization.
The increase in fluorescence signals generated by stimu-
lating fluo-4-AM loaded washed human platelets with
Cat K (20 nM) was used to determine the relative con-
tributions of PAR-3 and −4 activation to the intracellular
Ca2+ flux; these signals were compared with signals
generated by α-thrombin (1.0 UNHI/mL) and papain
(1.6 μM). The primary action of α-thrombin through
PAR-1 triggered a transient increase in cytoplasmic Ca2+
(See figure on previous page.)
Fig. 3 Effect of PAR-1 antagonist (SCH 79797), PAR-4 antagonist (transcinnamoyl- YPGKF-NH2), and PAR-3 antibody on cat K-induced platelet
aggregation and intracellular calcium measurements. (a) Human platelets were preincubated with the specific PAR-1 SCH 79797 antagonist (140
nM) for 30 min at 37 °C and evaluated in the aggregometer. Representative traces show the interference of SCH 79797 on cat K-induced platelet
aggregation. AP-PAR1 (0.2 µM) was completely inhibited. (b) The specific PAR-4 trans-cinnamoyl-YPGKF-NH2 antagonist (30 µM) inhibits human
platelet aggregation induced by cat K (20 nM). AP-PAR-4 (60 µM) was used as control. (c) Inhibitory effect of the PAR-3 antibody (0.02 µM) on cat
Kinduced human platelet aggregation. Platelets were preincubated with the PAR-3 antibody for 30 min at 37 °C and aggregation was measured.
Representative traces show the inhibition of the cat K effect (red and green lines). Papain-induced human platelet aggregation inhibition, black
line. The bar graph shows percentages of aggregation. Data are expressed as mean ± SEM from 3 independent experiments (**p<0.001, ***
p<0.0001). (d) Reverse transcriptase-PCR using total platelet RNA. Error bars indicate S.D. from triplicate samples. **p <0.01. (e). PAR-1, -3, and -4
were detected in washed platelets treated with cat K (20 nM), papain (1.6 µM), and α-thrombin (0.001 UNIH/500 µL) for 10 min at 37 °C; lysate
proteins were separated by 10% SDS-PAGE and electrotransferred to nitrocellulose membrane. Membranes were blocked and incubated with
anti-PAR1, anti-PAR3, anti-PAR4 rabbit primary antibodies, and anti-ß-actin (control). Antibody binding was visualized by chemiluminescence and
the relative levels of these proteins were determined by densitometric analysis. Data are expressed as mean ± SEM from 3 independent
experiments (**p<0.001). (f) Intracellular calcium measurements in ThrR -/- fibroblasts (absence in PAR-1). Increases in cytosolic calcium in
response to cat K (20 nM) and α-thrombin (0.001 UNIH/500 µL). (g) ThrR -/- fibroblasts (absence in PAR-3). Increases in cytosolic calcium in
response to cat K (20 nM) and α-thrombin (0.001 UNIH/500 µL). Inhibition of human cat K-activity on human platelet aggregation by E-64 (5 µM).
(h) ThrR -/- fibroblasts (absence in PAR-4). Increases in cytosolic calcium in response to cat K (20 nM), papain (1.6 µM), and α-thrombin (0.001
UNIH/500 µL)
Andrade et al. BMC Cancer  (2016) 16:173 Page 9 of 19
a f
g
h
b
c
d
e
Fig. 4 (See legend on next page.)
Andrade et al. BMC Cancer  (2016) 16:173 Page 10 of 19
ab e
c f
d
Fig. 5 Human platelet activation by cat K. Side and forward scatters of plasma rich in platelets (PRP) from different blood donors prepared under
the same conditions. PRP were stained with lineage markers: CD61-FITC (platelets) and Annexin V-PE (phosphatidyserine exposure) or the
appropriate isotype controls. PRP was analyzed by flow cytometry. Platelets were treated with apyrase (5.0 UNIH/mL). The areas Q1 and Q2
correspond to nonactivated and activated platelets, respectively. (a) Forward - by sidescatter profiles of events in PRP. Populations identified by
futher gating. CD61+ nonactivated platelets. Representative histogram of CD61+ platelet resident in PRP. (b) α-thrombin (0.001UNIH/mL), (c)
Platelets activated by cat K (20 nM), (d) cat B (0.2 µM), and (e) papain (1.6 µM), and their corresponding histograms. Note the increased number
of events in Q2 after stimulation with cat K, papain, and α-thrombin. Flow cytometric quantification of Annexin V-PE (beads were used for size
calibration). Each figure represents an analysis of 10,000 events with SSC (side scatter) on the abscissa, and FITC fluorescence intensities on the
ordinate. (f) The bar graph shows percentages of Annexin-V-PE. Data are expressed as mean ± SEM from 3 independent experiments (*p<0.05).
See also Fig. 1 and 3
(See figure on previous page.)
Fig. 4 Detection of signaling phosphoproteins by Immunoblot analysis and Ca2+ release into human platelets. (a) p-Src family, (b) p-FAK, and (c)
p-p38 washed platelets were treated with cat K (20 nM), papain (1.6 µM), and α-thrombin (0.001 UNIH/500µL) for 10 min at 37 °C; lysate proteins
were separated by 10 % SDS-PAGE and electrotransferred to nitrocellulose membranes. Membranes were blocked and incubated with rabbit
primary antibodies, anti-phospho-Src (Tyr-416), anti-Src, anti-phospho-FAK (Tyr-397), anti-FAK, anti- phospho-p38 MAPK, anti-p38 MAPK, and anti-
ß-actin. Antibody binding was visualized by chemiluminescence and the relative levels of these proteins were determined by densitometric
analysis. Papain (1.6 µM) slightly induced Src- and FAK-phosphorylation (2.1 ± 0.2 and 2.5 ± 0.4, respectively). Treatment with α-thrombin resulted
in increased Src phosphorylation with the pSrc/total Src ratio of 6.2 ± 0.4, and increased FAK phosphorylation with the pFAK/total FAK ratio of 6.3
± 0.2. The use of PAR-4 antagonist and PAR-3 antibody eliminated the Src Tyr416 phosphorylation by cat K (unpublished data). The
phosphorylation of p38 was required when human platelets were stimulated with cat K. Pre-treatment of platelets with PAR-3 antibody and PAR-
4 antagonist abolished the Src-Tyr-416 and FAKTyr- 397 phosphorylation. Data are expressed as mean ± SEM from 3 independent experiments
(*p<0.01,**p<0.001, ***p<0.0001). See also Fig. 1a. (d) The [Ca2+]i mobilization was measured as described. The arrow indicates when α-thrombin
was added to platelets (around 100 s). The washed platelets responded strongly with a transient rise in [Ca2+]i. (e) Cat K (20 nM) shows a calcium
spike followed by a sustained elevation in the fluorescence ratio. The presence of α-thrombin (1.0 UNIH/500µL) led to an increase in [Ca2+]i indicating
that the platelets induced Ca2+ release. (f) The papain (1.6 µM) response was similar to that from cat K, however, no substantial rise in [Ca2+]i was
detected with the addition of α-thrombin. (g) Cat K did not block the papain effect. Sustained elevation in the fluorescence ratio was observed. (h) Cat
L (0.2 µM) does not induce a detectable effect on Ca2+ mobilization; α-thrombin (1.0 UNIH/500µL) showed a strong response with a transient rise in
[Ca2+]i. Platelets were treated with indomethacin (0.1 mg/mL) to prevent thromboxane synthesis, which may also be affected by PKC [Ca2+]. The
mesurements were monitored by Fluo-4/AM (4 µM) intensity in a laser scanning confocal miscroscopy; scale bar = 10 µm
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concentration. The average amplitude of Ft/F0 was 6.8 ±
1.0 after the addition of α-thrombin (Fig. 4d). Cat K and
papain generated similar heights of calcium increase indu-
cing a prolonged robust response with an average Ft/F0 of
3.3 ± 1.0 for Cat K and 3.4 ± 1.0 for papain (Fig. 4e, f ). As
indicated in Fig. 4e, the addition of α-thrombin to Cat K
activated platelets induced a second increase in cytoplasm
Ca2+ concentration. However, when α-thrombin was
added to the papain preparation, no further Ca2+ increase
was observed (Fig. 4f).
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Fig. 6 Immunophenotype of breast cancer cells, from patients with Luminal B subtype, used in all experiments. Cells are shown under phase
contrast microscopy and indirect immunofluorescence for vimentin, cytokeratin, Ecadherin, N-cadherin, PAI-1, claudin 1, phalloidin, and DAPI
(blue, for nuclei). (a) Phase contrast–confluent culture of tumor cells with EMT (epithelialmesenchymal- transition) after 3 days. (b-e) Analysis of
epithelial and mesenchymal markers by confocal microscopy; cytokeratin, vimentin, Ecadherin, and N-cadherin, respectively. (f and g)
Representative flow cytometry histograms of PAI-1 and claudin 1 on tumor cells with EMT. The histogram on the left represents a control staining
using an isotype-matched control antibody. (h) Zymography for MMP-9, in conditioned medium, in EMT and epithelial cells isolated from women
with breast cancer. (i) Phase contrast— epithelial cells confluent culture after 2 days. (j and k) Analysis of epithelial marker cytokeratin. We
observed the cytoskeletal organization pattern when using phalloidin. (l) The expression of cat K is up-regulated in co-cultured breast cancer cells
and platelets. Cat K was assessed by immunoblotting. (m) Breast cancer cells in epithelial-mesenchimal transition co-cultured with platelets and
activated by cat K showed up-regultation of SHH, PTHrP, OPN, and TGF-ß expression, and increased phospho-Src. The graph represents the
densitometric analyses from the immunoblotting results. The results are represented as band intensities in arbitrary units relative to the respective
total loading control (ß-actin). (n) The flow cytometry results are reported as percentages of CD44 human-specific antibody in breast cancer cells,
and P-selectin in human platelets activated by cat K after exposure to breast cancer cells. See also Fig. 2
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Thus, Cat K and papain-induced an increase in cyto-
plasmic Ca2+ concentration through a sustained phase
and prolonged robust response. However, when platelets
were stimulated by Cat K (20 nM), followed by papain
(1.6 μM) (Fig. 4g), the effect of papain was maintained.
In contrast, Cat L, which shares 60 % similarity with Cat
K, did not significantly induce cytoplasmic Ca2+
mobilization (Fig. 4h); the subsequent addition of α-
thrombin resulted in a robust and transient Ca2+ release
from dense granules due to the action of α-thrombin
through pathways other than PARs activation, such as
the GpIb-V-IX complex [18].
Use of annexin V to detect human platelet activation by
Cat K
The process of platelet activation is linked to the in-
creased exposure of aminophospholipid phosphatidyl-
serine (PS) on the outer leaflet of the platelet
membrane. We tested the effects of Cat K, L, V, S,
and B on plasma rich in platelets (PRP) at 37 °C and
PS exposure using annexin V-PE. Dot plots of side
versus forward angle light scatter for non-activated
platelets and platelets labeled with CD61-FITC are
shown in Fig. 5a. α-Thrombin (0.001 UNHI/mL) was
used as control (Fig. 5b).
Cat K (20 nM) and B (0.2 μM) showed over 10 % ± 5
platelets bound to annexin-V (Fig. 5c-f). Interestingly,
papain (1.6 μM) (Fig. 5e, f ) activated 8 % ± 3 of platelets
and likewise, cat B induced the programmed anuclear
cell death process through a detectable release of lactate
dehydrogenase (Additional file 1: Figure S1b, c). No sig-
nificant alteration on PS content exposure was observed
after the incubation of platelets with cat V, L, and S
(data not shown).
The induced Cat K platelet dysfunction up-regulates the
Hedgehog ligand and growth factors in cells from pa-
tients with luminal B breast cancer
To extend these findings to human diseases such as
breast cancer, we evaluated the possible correlations be-
tween blood coagulation abnormalities, such as platelet
activation, and breast cancer cells expressing Cat K dur-
ing metastasis to bone.
We investigated Hedgehog ligands in a model based on
the co-culture of breast cancer cells and washed human
platelets solutions activated by Cat K (20 nM).
The phenotype of 15 tumor specimens collected from
patients with luminal B type breast carcinoma was
previously confirmed. Ten of these patients showed
different stages in the process of epithelial to mesen-
chymal transition (EMT) and elevated platelet counts,
with an average count of 635 (x 103/μL) and range
between 480–844 (× 103/μL) (Additional file 1: Table
S2). Epithelial and mesenchymal markers involved in
EMT were assayed by immunolocalization, confocal
microscopy, and fluorescence-activated cell sorting.
Analyses indicated that the cytokeratin (epithelial
marker) and vimentin (fibroblast marker) were coloca-
lized on the cell surface (Fig. 6a-c). E-cadherin levels
were also reduced in comparison with N-cadherin
(Fig. 6d, e). The plasminogen activator inhibitor-1
(PAI-1; Serpine 1, mesenchymal marker) was consist-
ently detected (upregulated); the claudin 1 ephitelial
marker was also detected as downregulated (Fig. 6f, g).
These results eliminated the hypothesis that breast
tumor cells have infiltrating carcinoma-associated fi-
broblasts, and therefore, confirming the EMT process.
The zymography analysis revealed increased matrix
metalloproteinase-9 (MMP-9) secretion (Fig. 6h) suggesting
an increased capacity of mesenchymal-like phenotype cells
to degrade the extracellular matrix (ECM) and invade the
surrounding environment. The remaining five patients with
the epithelial phenotype of positive cytokeratin and negative
vimentin (Fig. 6i-k) showed normal platelet counts with an
average of 290 (x 103/μL) and range between 241 and 395
(× 103/μL) (Additional file 1: Table S2).
Human mesenchymal-like phenotype cells were suc-
cessfully culture-expanded reaching greater than 90 %
confluence in 5 days through weekly passages. The
characterization of primary cells was performed on the
third passage; this allowed these cells to present a very
similar phenotype to that of cells in the original tissues
from women with luminal B breast cancer. Mycoplasma
contamination was not observed in any of the processed
tissues. The expression of Cat K pro-enzyme (37 kDa)
was identified in mesenchymal-like phenotype cell ex-
tracts from patients with breast cancer and in human
platelets; the expression of Cat K was detected through
densitometry analysis in both cells in co-culture at 4.2 ±
0.2 (Fig. 6l). The cathepsin cysteine protease activity was
detectable in the medium of mesenchymal-like pheno-
type cells (Additional file 1: Figure S2). Subsequently,
mesenchymal-like phenotype cells from women with
breast cancer and washed human platelets activated by
Cat K were co-cultured. Western blot analysis of these
co-cultured cells, after Cat K addition for 24 h, revealed
a single band with an apparent molecular mass of
50 kDa, consistent with the presence of SHH in these
cells (Fig. 6m). In contrast, SHH was not observed in
epithelial cells from patients with breast carcinoma (data
not shown). Interestingly, SHH was observed in Cat K-
activated human platelets used in co-culture (p ≤ 0.001,
Fig. 6m). Unprecedentedly, this cross-talk between the
mesenchymal-like phenotype cells and Cat K activated
platelets showed SHH expression in human platelets.
Furthermore, Cat K activated platelets up-regulated fac-
tors that amplify the paracrine Hedgehog signaling.
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Breast cancer cells in co-culture with Cat K activated
platelets played a critical role in up-regulating the ex-
pression of PTHrP and Src (p ≤ 0.01, Fig. 6m). The up-
regulation in PTHrP expression was 2-fold higher in the
mesenchymal-like phenotype cells (5.7 ± 1.2, p ≤ 0.01) than
in epithelial cells (3.4 ± 0.4, p ≤ 0.01 – Additional file 1:
Figure S4) from breast carcinoma luminal B tissues. An-
other important protein in the Hedgehog signaling is
OPN, which is reported by Das et al. [36] as a “bone me-
tastasized signature”. We observed that unlike Cat K acti-
vated platelets, the mesenchymal-like phenotype cells
presented increased OPN expression (4.3 ± 0.9, p ≤ 0.01)
(Fig. 6m). Conversely, no difference in OPN expression
was detected in epithelial carcinoma cells (data not
shown). Thus, we investigated whether platelets activated
by Cat K had a direct impact on the expression of Src in
breast carcinoma cells co-cultured with these platelets for
24 hr. The results obtained using phospho-Src monoclo-
nal antibody showed that platelets activated by Cat K led
to a marked increase in Src expression in mesenchymal-
like phenotype cells (4.5 ± 1.0, Fig. 6m). The Western blot
analysis of the TGFβ expression in Cat K activated plate-
lets showed an evident direct regulation of TGFβ resulting
from contact between platelets activated by Cat K and
mesenchymal-like phenotype cells (5.56 ± 0.8, Fig. 6m). Fi-
nally, we detected elevated levels of CD44 expression in
breast carcinoma cells co-cultured with washed platelets
activated by Cat K. Consequently, we observed an
a
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Fig. 7 Hypothesized molecular coordination between Cat-K-induced platelet aggregation and crosstalk with epithelial-mesenchimal-like cells
from patients with breast cancer. The activation and release of cat K occurs in epithelial-mesenchimal transition cells in breast cancer subtype
Luminal B. (a) Breast cancer cells cultured with human platelets and activated by cat K and α-thrombin. Phase contrast images of epithelial-
mesenchimal-like cells co-cultured with platelets activated by cat K for 24 h. (b) Cat K may activate PAR-3 and PAR-4 in human platelets, by
receptor cleavage, and trigger platelet aggregation. Activated PAR-3 and PAR-4 can perpetuate the cohesion of tumor cells during
heteroaggregation with increase in P-selectin and CD44. The crosstalk between platelets activated by cat K and epithelialmesenchimal tumor cells
form microaggreates and promote up-regulation of Hedgehog ligands and growth factors such as SHH, OPN, PTHrP, and TGFß. (c) Mammary stroma
(1), intravasation (2), cat K secretion by epithelialmesenchimal tumor cells (3), and activate human platelets that could directly affect the expression of
the ligands of Hedgehog signaling, reported as an aberrantly activated pathway in breast cancer and related to bone metastasis markers
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increased P-selectin expression in human platelets (p ≤
0.01, Fig. 6n).
Discussion
Proteases and PARs have crucial roles in hemostasis, in-
flammation, pain, and cancer. However, the spectrum of
proteases that are activated in these conditions is unclear,
and their identity, cellular origin, mechanism of action,
and causative roles of specifically activated proteases are
not defined. Equally, PARs are recognized and activated
by proteases such as cysteine cathepsins, which have
diverse physiopathological functions. Certain cysteine
cathepsins, such as Cat K, L, and B, are secreted as soluble
enzymes in pericellular environments where they remain
fully active [2, 24, 37, 38].
As previously mentioned, Cat K is a highly potent colla-
genase with predominant papain-like characteristics that
is expressed in osteoclasts. It is present in most epithelial
tissues, functions in the lysosomal and extracellular envi-
ronments as a soluble enzyme, and shows optimal activity
at pH between 5.0 and 8.0. This enzyme has been impli-
cated in osteoporosis, arthritis, atherosclerosis, metabolic
function, and breast cancer [22, 24, 36, 39, 40].
Platelets, the cells’ chief mediators of hemostasis, are
important in these processes, and express three of the
four known PARs, PAR-1, −3, and −4. Some studies have
demonstrated the action of cathepsins on PARs: the hu-
man cat S cleaves PAR-2 in colitis while [38] plant cyst-
eine protease cathepsins (bromelain, ficin, and papain)
activate PAR-2 and PAR-4 in itching processes [41, 42].
Thus, we evaluated the ability of the human cysteine
cathepsins K, L, B, S, and V to induce human platelet ag-
gregation using papain as a cysteine protease prototype.
Our results show that Cat K, but not L, B, S, and V, induced
human platelet aggregation in a dose-dependent manner.
Although all five human cathepsins – K, S, L, V, and B –
have conserved three-dimensional structure and similar
substrate specificity, distinct amino acid preferences that
differentiate each enzyme were identified in this study. We
used synthetic substrates that mimic the cleavage sites for
PARs activation. Cysteine cathepsins - K, S, L, V, and B -
generally accept Arg and Lys at the P1 position, which are
key amino acids recognized by thrombin when forming
tethered ligand sequences for the activation of receptors.
Cat L, S, and V clearly show unspecific cleavage sites in the
three substrates. In addition, cat L did not hydrolyze the
substrate derived from PAR-4. Similarly, cat B did not
hydrolyze these substrates but was the only cysteine cathep-
sin previously investigated in human platelet aggregation.
Honn et al. [16] described the association between tumor
cells and platelet aggregation using papain as a cat B-
mimicking agent and concluded that cat B released from
tumor cells induced human platelet aggregation. The crys-
tal structure resolution of cat B [43] showed that human
cysteine cathepsins share great sequence similarity, but also
contain variable portions that confer important differences
in proteolytic specificity and participation in regulatory
mechanisms [7, 8].
Unlike the other enzymes tested, Cat K displayed the
most distinguishing substrate specificity. Cat K exclusively
cleaves PAR-3 and PAR-4 peptides at the Lys-Thr and
Arg-Gly bonds, mimicking the activity of α-thrombin on
these substrates, and demonstrates its role as possible
PAR-3 and PAR-4 agonists. On the other hand, the pro-
teolytic nature of the Cat K effect on human platelet
aggregation was demonstrated using the classical cysteine
proteinase inhibitors, E-64, LMWK, and HMWK, and
correlating the complete inhibition of Cat K activity to the
absence of platelet aggregation. This result reinforces the
idea that PARs cleaved by Cat K initiate platelet aggrega-
tion. Interestingly Cat K did not impair α-thrombin-
induced platelet aggregation, indicating that Cat K acts on
PARs but does not hinder the PAR-1 receptor. The
repeated or continuous exposure of washed platelets to
papain and Cat L, V, B, and S alters the PARs response to
α-thrombin in such a way that the cellular response is
dampened or completely switched off. These results are in
agreement with the observed kinetic parameters and show
that only Cat K and papain-induced platelet aggregation
through PAR-3 and PAR-4 activation, respectively. Simi-
larly, papain does not interfere with the Cat K-induced
human platelet aggregation but rather Cat K reduced the
papain response. These results indicate that Cat K acts on
PAR-3 and PAR-4; however, the effect of papain is only
through the activation of PAR-4, as observed by Reddy
and Lerner [41].
To reinforce the involvement of PARs-3 and −4 on
the effects of Cat K, we used PAR-1 (SCH 79797) and
PAR-4 (trans-cinnamoyl-YPGKF-NH2) specific antago-
nists and PAR-3 antibody. Thus, the aggregation of hu-
man platelet elicited by Cat K was completely blocked
by the PAR-3 antibody and PAR-4 antagonist. Contrary
to the expected results, the specific PAR-1 antagonist,
SCH 79797, was shown to interfere with Cat K-induced
platelet aggregation. Perhaps one of the PARs, such as
PAR-3, regulates the PAR-1 signaling through receptor
dimerization as described by McLaughlin et al. [44].
The presence of a functional PAR-3 in human platelets
remains unclear, however, PAR-3 is also a α-thrombin
substrate; its expression in human platelets has been de-
scribed by others authors [19–21]. PAR-3 is considered a
non-signaling receptor and its agonist proteases remain
uncharacterized [45]. It is important to mention that our
pharmacological assay data were confirmed by the ready
detection of PAR-3 mRNA transcripts in human plate-
lets through reverse transcription-PCR. In addition,
PAR-1, PAR-3, and PAR-4 were detected by Western
blot in washed platelets treated with Cat-K, α-thrombin,
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and papain; an increased PAR-3 expression was con-
firmed by densitometry analysis in platelets treated with
Cat K. To support these results, we used fibroblast cells
from ThrR −/− knockout mice in conjunction with se-
lective antagonists for PAR-1, −3, and −4. No substantial
increase in [Ca2+]c was detected in ThrR
−/− knockout
mice compared to that in wild-type mice.
Collectively, these results clearly indicate that Cat K acts
as an agonist to PAR-3 and PAR-4 and induces platelet ag-
gregation; moreover, it indicates that the PAR-3 antibody
and PAR-4 antagonist inhibited this aggregation.
Hence, we hypothesize that PAR-3 activation by Cat K
in human platelets may represent a specific mechanism
that drives target cells to express transmembrane signal-
ing triggers in inflammation or cancer processes, such as
breast cancer.
Moreover, we do not discard the possibility that PAR-3
is a PAR-4 cofactor and, possibly, a PAR-1 cofactor. The
Coughlin research group [45-47] reports that mouse
PAR-3 did promote cleavage and activation of human
PAR-4 as effectively as it did on mouse PAR-4. Because
human platelets express PAR-1 and PAR-4, but much
less PAR-3, and because PAR-1 and PAR-4 can inde-
pendently mediate thrombin signaling, we evaluated the
PAR-3 activation and its possible consequent transmem-
brane signaling.
This investigation was based on the fact that the
Src/FAK adhesion focal complex usually includes the
first proteins implicated in signaling pathways medi-
ated by PARs −1, −3, and −4 in platelets, e.g. platelets
aggregate and adhere to the site of vascular injuries
[21, 48]. Our findings confirm an increase in Src-Tyr-
416 and FAK-Tyr-397 phosphorylation in washed hu-
man platelets stimulated with Cat K. Moreover, focal
adhesions act as a signaling center mediating multiple
dynamic protein-protein interactions and conse-
quently regulating the assembly and disassembly of
focal adhesion sites, such as those with endothelial
and others cells, which are essential in the control of
platelet movements [49]. It is important to note that
the pre-treatment of platelets with PAR-3 antibody
and PAR-4 antagonist abolished the phosphorylation
of Src-Tyr-416 and FAK-Tyr-397.
It is well established that α-thrombin induces MAPK
activation in human platelets. Human platelets contain
several members of the MAPK family, including p38.
The p38 MAPK activation is observed as a consequence
of Src/FAK phosphorylation [49–51]. The role of p38 in
platelets is associated with platelet dispersion and cyto-
skeleton reorganization; the release of Ca2+ by dense-
granules occurs as a consequence and induces responses
for platelet activation and aggregation [49–51]. The in-
crease in p38-MAPK phosphorylation in washed plate-
lets pre-treated with Cat K was confirmed based on the
results using α-thrombin as a control. In addition, our
data show that, similar to papain, Cat K induces a ro-
bust, sustained, and prolonged response to Ca2+ increase
that is characteristic of PAR-4 activation, and required
for the exposure of phosphatidylserine (PS) by platelets
and acceleration of platelet activation [42, 52]. Further-
more, the α-thrombin ability to increase transient Ca2+
mobilization was blocked in the presence of papain, but
not in the presence of Cat K. Interestingly, when we
evaluated the effect of papain in the presence of Cat K
on platelet aggregation, the sustained phase of Ca2+
mobilization was prolonged and similar to that observed
in platelet aggregation when Cat K does not block the
papain-induced platelet aggregation.
At this point, we investigated platelet functions using
washed human platelets. Human platelets were washed to
exclude plasma enzymes and prevent undesired platelet
functions [53]. Plasma rich in platelets (PRP) was used in
the detection of platelet activation because it contains
plasma enzymes and interferes with spontaneous aggrega-
tion by competing for sites in PARs. We compared different
cathepsins and their ability to induce platelet activation
through the exposure of the anionic inner PS on the plate-
let’s surface. Therefore, Cat K and papain-induced human
platelet activation were observed by the detection of posi-
tive PS-annexin-V. This Cat K ability could be correlated
with the enhancement of platelet aggregation induced by
the in vitro tumor cells medium; this result indicates a dys-
regulation between the high activity of cysteine proteases
and low levels of their respective endogenous inhibitors,
showing their potential metastatic effect in tumor cells in
vivo [1, 16, 54, 55].
Our results suggest the involvement of Cat K-induced
platelet aggregation in human diseases such as breast can-
cer. Breast cancer comprises clinically and molecularly
distinct tumor subgroups that differ in cell histology and
biology and show divergent clinical phenotypes that ham-
per phase III trials such as those utilizing Cat K inhibitors.
We chose the luminal B subtype of breast cancer because
it is usually more associated with bone metastasis than
other types of breast cancer [54]. Here we correlate
epithelial-mesenchymal-like transition cells, from breast
cancer patients, with Cat K-induced platelet aggregation
(Fig. 7a). Ten of these patients had elevated platelet
counts. The co-culture of breast cancer cells with washed
human platelets activated by Cat K up-regulates SHH and
the expression of factors, such as PTHrP and TGFβ, that
amplify the paracrine Hedgehog signaling. In addition, we
detected an increase in OPN, which is a component of the
“bone metastasis signature” in breast cancer cells, i.e.
breast cancer cells that metastasized to the bone show in-
creased OPN expression [36, 40]. We also observed an in-
crease in Src phosphorylation, a central non-receptor
tyrosine kinase involved in bone metastasis. Our
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experiments also show elevated levels of CD44 expression
in tumor cells, and P-selectin in washed platelets activated
by Cat K in co-culture, corroborating the observed expres-
sion of these glycoproteins in metastatic tumor cells. Con-
versely, CD44 is a marker for stem cell-like cells that
indicates cellular heterogeneities and, consequently, is re-
lated to worse outcomes, therapeutic resistance, and meta-
static progression [55]. Our study reveals that human
platelets activated by Cat K-tumor cells with epithelial-
mesenchymal-like transition phenotype predominantly
up-regulate SHH, PTHrP, TGFβ, Src, OPN, CD44, and P-
selectin, and impact the malignancy of breast cancer cells
possibly contributing to their tropism to bones.
These results corroborate reports that Cat K is import-
ant in platelet-tumor cell cross-talk, which induces
platelet aggregation via PAR-3 and PAR-4 (Fig. 7b, c).
Moreover, our results enhance the understanding of the
molecular coordination between activated platelets and
tumor cells, which can support metastasis in secondary
sites.
Conclusion
We concluded that Cat K might activate PAR-3 and
PAR-4 mimicking the activity of α-thrombin on these
substrates. Cat K-induces platelet aggregation in a
dose-dependent manner and triggers Src and p38 phos-
phorylation and Ca2+ influx from the contents of plate-
lets inducing platelet dysfunction, which could facilitate
the interaction with breast tumor cells. We have uncov-
ered a mechanism involving a successive series of
signaling events linked to Cat K-induced platelet activa-
tion and aggregation when co-cultured with breast can-
cer cells from patients with luminal B carcinoma. With
further advances in our understanding of protease func-
tions, origin, temporal release, and properties coupled
with improvements in protein engineering, we expect
that other therapeutic cysteine protease inhibitors will
gain regulatory approval for use in the early stages of
breast cancer [56–58]. This therapeutic approach will
represent a significant contribution to the treatment of
this disease.
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